@lixte.com
Lixte Biotechnology Holdings, Inc.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
Icon
JPEG
About
Description
Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a drug discovery company dedicated to creating better treatments for cancer. Their lead clinical compound is LB-100, a unique and proprietary protein phosphatase inhibitor.
LB-100 has the potential to revolutionize cancer treatment as it can be used alone or in combination with standard anti-cancer therapies such as cytotoxic drugs, radiation, and immune checkpoint blockers. Protein phosphatases, especially protein phosphatase 2A (PP2A), play a crucial role in cell growth, division, and death. Lixte has demonstrated that their inhibition using LB-100 is not only well-tolerated in patients but also associated with significant tumor shrinkage and the arrest of tumor progression.
LB-100 has shown effectiveness against a spectrum of human cancers that have abnormalities in PP2A function. It enhances the effectiveness of cytotoxic drug and radiation therapies without increasing toxicity. Additionally, it activates cytotoxic T cells and CAR-T cells, significantly increasing the effectiveness of PD-1 immune-checkpoint blockade.
Lixte's immediate goal is to demonstrate the clinical therapeutic benefit of LB-100 in major cancers that affect large populations. They are currently conducting trials for various types of cancer, including myelodysplastic syndrome and advanced soft tissue sarcoma. In collaboration with renowned institutions like the Moffitt Cancer Center and City of Hope, Lixte is actively working towards developing innovative and effective treatments to improve the lives of cancer patients
Company Type
Public Company
Company Size
2-10
Year Founded
2006
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories